AndreaBozzo/ceres-open-data-index huggingface dataset:
Child and Family Services Reviews Key Children's Bureau and Federal Contractor Staff

The Child and Family Services Reviews (CFSRs) are administered by the Children's Bureau, U.S. Department of Health and Human Services. The following is contact information for the Children's Bureau CFSR leadership and data team, and the federal contractors who provide support to the CFSRs.

Children's Bureau

1250 Maryland Avenue, S.W
8th Floor
Washington, DC 20024
(202) 205-8618

Children's Bureau Central and Regional Office Staff

Contact information for Children's Bureau Central and Regional Office staff can be found at /oro/about/contact.

Review Leadership

Angela Adams
Bob Baptista
Misty Carlyle
Yolanda Fripp
James Gregory
Jennifer Miller Haight
Angela Ivey
Elizabeth Jones-Ferguson
Sylvia Kim
Richard Longoria
Danielle McConaga
Allison McDowell
Linda Mitchell
Beth Pierce

Data Team

Telisa Burt
Malcolm Hale
John Hargrove
Steven Lao
Sharon Newburg-Rinn
Roger Stanton
Tammy White

Child Welfare Reviews Project
5515 Security Lane, Suite 800
North Bethesda, MD 20852-5007
(301) 495-1080

Metadata-only record linking to the original dataset. Open original dataset below.
Compound 528651: 3-Ketovaleric acid, oxime, TMS

Chemical compound data from PubChem database. IUPAC Name: trimethylsilyl 3-trimethylsilyloxyiminopentanoate. Molecular Formula: C11H25NO3Si2. Molecular Weight: 275.49. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
NNDSS - TABLE 1Q. Hepatitis B, perinatal infection to Hepatitis C (viral, acute), Probable

NNDSS - TABLE 1Q.  Hepatitis B, perinatal infection to Hepatitis C (viral, acute), Probable - 2019. In this Table, provisional cases* of notifiable diseases are displayed for United States, U.S. territories, and Non-U.S. residents. 

Note: 
This table contains provisional cases of national notifiable diseases from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data from the 50 states, New York City, the District of Columbia and the U.S. territories are collated and published weekly on the NNDSS Data and Statistics web page (https://wwwn.cdc.gov/nndss/data-and-statistics.html). Cases reported by state health departments to CDC for weekly publication are provisional because of the time needed to complete case follow-up. Therefore, numbers presented in later weeks may reflect changes made to these counts as additional information becomes available. The national surveillance case definitions used to define a case are available on the NNDSS web site at https://wwwn.cdc.gov/nndss/. Information about the weekly provisional data and guides to interpreting data are available at: https://wwwn.cdc.gov/nndss/infectious-tables.html. 

Footnotes:
U: Unavailable — The reporting jurisdiction was unable to send the data to CDC or CDC was unable to process the data.
-: No reported cases — The reporting jurisdiction did not submit any cases to CDC.
N: Not reportable — The disease or condition was not reportable by law, statute, or regulation in the reporting jurisdiction.
NN: Not nationally notifiable — This condition was not designated as being nationally notifiable.
NP: Nationally notifiable but not published — CDC does not have data because of changes in how conditions are categorized.
Cum: Cumulative year-to-date counts.
 Max: Maximum — Maximum case count during the previous 52 weeks.
 * Case counts for reporting years 2018 and 2019 are provisional and subject to change. Cases are assigned to the reporting jurisdiction submitting the case to NNDSS, if the case's country of usual residence is the US, a US territory, unknown, or null (i.e. country not reported); otherwise, the case is assigned to the 'Non-US Residents' category. For further information on interpretation of these data, see https://wwwn.cdc.gov/nndss/document/Users_guide_WONDER_tables_cleared_final.pdf. 
† Previous 52 week maximum and cumulative YTD are determined from periods of time when the condition was reportable in the jurisdiction (i.e., may be less than 52 weeks of data or incomplete YTD data). 
§ For acute Hepatitis C, only confirmed cases were verified.
COVID-19 State Profile Report - Alabama

<b>After over two years of public reporting, the State Profile Report will no longer be produced and distributed after February 2023. The final release was on February 23, 2023. We want to thank everyone who contributed to the design, production, and review of this report and we hope that it provided insight into the data trends throughout the COVID-19 pandemic.
Data about COVID-19 will continue to be updated at <a href='https://covid.cdc.gov/covid-data-tracker/#datatracker-home' >CDC’s COVID Data Tracker</a>.
 </b>

<p>
The State Profile Report (SPR) is generated by the Data Strategy and Execution Workgroup in the Joint Coordination Cell, in collaboration with the White House. It is managed by an interagency team with representatives from multiple agencies and offices (including the United States Department of Health and Human Services (HHS), the Centers for Disease Control and Prevention, the HHS Assistant Secretary for Preparedness and Response, and the Indian Health Service). The SPR provides easily interpretable information on key indicators for each state, down to the county level.
 </p>

It is a weekly snapshot in time that:
<ul>
<li>Focuses on recent outcomes in the last seven days and changes relative to the month prior</li>
<li>Provides additional contextual information at the county level for each state, and includes national level information</li>
<li>Supports rapid visual interpretation of results with color thresholds</li>
</ul>
Debate: Transfusing to normal hemoglobin levels improves outcome

Red cells are uniquely designed to transport oxygen and facilitate oxygen uptake by systemic tissues. Blood transfusions are thus logical therapeutic choices in patients who exhibit signs of oxygen debt. A small number of studies that have addressed patients with metabolic or physiologic signs of oxygen debt or regional ischaemia suggest that liberal blood transfusion strategies improve outcome. Therefore, armed with an understanding of the variety of clinical presentations characterising oxygen debt, as well as an appreciation of the risks involved, blood transfusions should be considered in all critically ill patients. This includes the consideration of liberalized hemoglobin triggers and hemoglobin thresholds in normal ranges.
A hierarchical statistical model for estimating population properties of quantitative genes

Background
          Earlier methods for detecting major genes responsible for a quantitative trait rely critically upon a well-structured pedigree in which the segregation pattern of genes exactly follow Mendelian inheritance laws. However, for many outcrossing species, such pedigrees are not available and genes also display population properties.
        
        
          Results
          In this paper, a hierarchical statistical model is proposed to monitor the existence of a major gene based on its segregation and transmission across two successive generations. The model is implemented with an EM algorithm to provide maximum likelihood estimates for genetic parameters of the major locus. This new method is successfully applied to identify an additive gene having a large effect on stem height growth of aspen trees. The estimates of population genetic parameters for this major gene can be generalized to the original breeding population from which the parents were sampled. A simulation study is presented to evaluate finite sample properties of the model.
        
        
          Conclusions
          A hierarchical model was derived for detecting major genes affecting a quantitative trait based on progeny tests of outcrossing species. The new model takes into account the population genetic properties of genes and is expected to enhance the accuracy, precision and power of gene detection.
Compound 527101: Methyl 5-oxo-5-[4-(trifluoromethyl)phenyl]pentanoate

Chemical compound data from PubChem database. IUPAC Name: methyl 5-oxo-5-[4-(trifluoromethyl)phenyl]pentanoate. Molecular Formula: C13H13F3O3. Molecular Weight: 274.23. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 525543: 2-(((1,1-Dimethylethyl)dimethylsilyl)oxy)-3-(1-methylethyl)quinoxaline

Chemical compound data from PubChem database. IUPAC Name: tert-butyl-dimethyl-(3-propan-2-ylquinoxalin-2-yl)oxysilane. Molecular Formula: C17H26N2OSi. Molecular Weight: 302.5. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 527740: 2,2,2-Trichloroethyl dodecanoate

Chemical compound data from PubChem database. IUPAC Name: 2,2,2-trichloroethyl dodecanoate. Molecular Formula: C14H25Cl3O2. Molecular Weight: 331.7. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
CBHSQ Data Brief: Peer services supported through State Targeted Response to the Opioid Crisis grants

This CBHSQ Data Brief presents findings from the evaluation of the State Targeted Response to the Opioid Crisis Grants (Opioid STR) that describe how funding was used to support peer services for people with or recovering from opioid use disorder (OUD).  The evaluation revealed that most Opioid STR grantees used funds to implement, expand, or enhance peer services. The peer services most commonly provided were coaching, mentoring, and providing information and referrals to relevant services.The Opioid STR was the predecessor of the State Opioid Response (SOR) grant program and informed its development. At the start of SOR, grantees were expected to provide an array of services based on needs identified in their STR strategic plan. SOR addresses the opioid overdose crisis by providing resources to states and territories for increasing access to FDA-approved medications for the treatment of opioid use disorder (MOUD), and for supporting the continuum of prevention, harm reduction, treatment, and recovery support services.
Compound 525562: N,N-Dimethyl-N'-(3-bromophenyl)-p-methoxybenzamidine

Chemical compound data from PubChem database. IUPAC Name: N'-(3-bromophenyl)-4-methoxy-N,N-dimethylbenzenecarboximidamide. Molecular Formula: C16H17BrN2O. Molecular Weight: 333.22. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
High daily doses of benzodiazepines among Quebec seniors: prevalence and correlates

Background
          Use of high daily doses of benzodiazepines is generally contraindicated for seniors. While both patient and physician factors may influence the use of high daily doses, previous research on the effect of patient factors has been extremely limited. The objectives of this study were to determine the one year prevalence of use of high daily doses of benzodiazepines, and examine physician and patient correlates of such use among Quebec community-dwelling seniors.
        
        
          Methods
          Patient information for 1423 community-dwelling Quebec seniors who participated in the Canadian Study of Health and Aging was linked to provincial health insurance administrative data bases containing detailed information on prescriptions received and prescribers.
        
        
          Results
          The standardized one year period prevalence of use of high daily doses of benzodiazepines was 7.9%. Use of high daily doses was more frequent among younger seniors and those who had reported anxiety during the previous year. Patients without cognitive impairment were more likely to receive high dose prescriptions from general practitioners, while those with cognitive impairment were more likely to receive high dose prescriptions from specialists.
        
        
          Conclusion
          High dose prescribing appears to be related to both patient and physician factors.
Central Line-Associated Bloodstream infections (CLABSI) in California Hospitals

This dataset includes central line-associated bloodstream infection (CLABSI) data reported by California hospitals to the California Department of Public Health (CDPH), Healthcare-Associated Infections (HAI) Program, via the Centers for Disease Control and Prevention (CDC) National Healthcare Safety Network (NHSN). Hospital types include acute care, critical access, long-term acute care, free-standing rehabilitation hospitals, as well as acute rehabilitation units that report data separately.

CLABSI data for each hospital include the number of infections observed (reported) and predicted (based on national baseline data), the number of central line-days, the Standardized Infection Ratio (SIR) and associated 95% confidence intervals, and statistical interpretation to show whether CLABSI incidence was the same (no different), better (lower), or worse (higher) than the national baseline. Central line insertion practices (CLIP) adherence percent for each hospital is calculated from data reported by all critical care locations (i.e., critical care areas, neonatal critical care, and one special care area, "Oncology - Medical/Surgical Critical Care"). In 2021, the CLIP reporting requirement to CDPH via NHSN was discontinued.

CLABSI SIRs are influenced by clinical and infection control practices related to central line insertion and infection control maintenance practices, patient-based risk factors, and surveillance and reporting methods. Health and Safety Code section 1288.55(a)(2) requires general acute care hospitals to report to CDPH all cases of CLABSI identified in their facilities. 

For general information about NHSN, surveillance definitions, and reporting requirements for CLABSI, please visit: https://www.cdc.gov/nhsn/index.html 

To link the CDPH facility IDs with those from other Departments, including OSHPD, please reference the "Licensed Facility Cross-Walk" Open Data table at: https://data.chhs.ca.gov/dataset/licensed-facility-crosswalk.

For information about healthcare-associated infection prevention progress in California hospitals and statewide prevention goals, please visit: https://www.cdph.ca.gov/Programs/CHCQ/HAI/Pages/AnnualHAIReports.aspx
HSH Shelter Waitlist

<strong>A. SUMMARY</strong>
Source of data for the Shelter Reservation Waitlist. Please view the below website for more information on the shelter reservation system:
-  <u><a href="https://hsh.sfgov.org/services/how-to-get-services/accessing-temporary-shelter/adult-temporary-shelter/shelter-reservation-waitlist/">Shelter Reservation Website</a></u>

For more information on Housing Assistance, please view the website below:
-   <u><a href="https://hsh.sfgov.org/services/how-to-get-services/referrals-and-housing-assistance/">Referrals and Housing Assistance</a></u>

<strong>B. HOW TO USE THIS DATASET</strong>
Your waitlist ID is your eight-digit birthdate (MMDDYYYY) and your initials. For example, if your name is Michael Jackson and you were born on August 29, 1958, your waitlist ID is 08291958MJ.

It may take 24 hours for your name to show up on the list after you register.

If you are at the top of the waitlist there will be a note in the row with your Waitlist ID. Since some beds are gender-specific, it might be your turn even if your name does not appear in the first few rows. Make sure you search your waitlist ID to see if there are instructions to call in. Learn how to claim your bed on the FAQs page.

If you haven’t already registered, get instructions about how to sign up online or by phone. You can only have one entry in the waitlist at one time.
Table 23. Needing But Not Receiving Treatment for Alcohol Use in the Past Year among Persons Aged 12 or Older, by State and Substate Regions: Percentages, Annual Averages Based on 2010, 2011, and 2012 NSDUHs

Table 23. Needing But Not Receiving Treatment for Alcohol Use in the Past Year among Persons Aged 12 or Older, by State and Substate Regions: Percentages, Annual Averages Based on 2010, 2011, and 2012 NSDUHs
Compound 530230: Bis(trimethylsilyl) 2,3-pyridinedicarboxylate

Chemical compound data from PubChem database. IUPAC Name: bis(trimethylsilyl) pyridine-2,3-dicarboxylate. Molecular Formula: C13H21NO4Si2. Molecular Weight: 311.48. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 525831: N,N-Dimethyl-N'-(4-ethoxyphenyl)-propionamidine

Chemical compound data from PubChem database. IUPAC Name: N'-(4-ethoxyphenyl)-N,N-dimethylpropanimidamide. Molecular Formula: C13H20N2O. Molecular Weight: 220.31. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
COVID-19 Hospital Data Coverage Report

<p><b>After May 3, 2024, this dataset and webpage will no longer be updated because hospitals are no longer required to report data on COVID-19 hospital admissions, and hospital capacity and occupancy data, to HHS through CDC’s National Healthcare Safety Network. Data voluntarily reported to NHSN after May 1, 2024, will be available starting May 10, 2024, at <a href="https://covid.cdc.gov/covid-data-tracker/#hospitalizations-landing">COVID Data Tracker Hospitalizations</a>.</b></p>

This report shows data completeness information on data submitted by hospitals for the previous week, from Friday to Thursday. The U.S. Department of Health and Human Services requires all hospitals licensed to provide 24-hour care to report certain data necessary to the all-of-America COVID-19 response. The report includes the following information for each hospital:
<ul>
<li>The percentage of mandatory fields reported.</li>
<li>The number of days in the preceding week where 100% of the fields were completed.</li>
<li>Whether a hospital is required to report on Wednesdays only.</li>
<li>A cell for each required field with the number of days that specific field was reported for the week.</li>
</ul>
Hospitals are key partners in the Federal response to COVID-19, and this report is published to increase transparency into the type and amount of data being successfully reported to the U.S. Government.</li>
</ul>
<li>9/12/2021 - Added a Summary page and broke out the attached Excel, tabbed spreadsheet into its own reports.  You can access the Summary page with this link:
https://healthdata.gov/stories/s/ws49-ddj5</li>
<li>6/17/2023 - With the new 28-day compliance reporting period, CoP reports will be posted <b>every 4 weeks</b>.</li><br>
</ul>
</ul>
Source:<b> HHS Protect, U.S. Department of Health & Human Services</b>
Modulation of cathepsin G expression in severe atopic dermatitis following medium-dose UVA1 phototherapy

Background
          During the last decade, medium-dose UVA1 phototherapy (50 J/cm2) has achieved great value within the treatment of severe atopic dermatitis (AD). The purpose of our study was to investigate to what extent UVA1 irradiation is able to modulate the status of protease activity by the use of a monoclonal antibody labeling cathepsin G.
        
        
          Methods
          In order to further elucidate the mechanisms by which medium-dose UVA1 irradiation leads to an improvement of skin status in patients with AD, biopsy specimens from 15 patients before and after treatment were analyzed immunohistochemically for proteolytic activation.
        
        
          Results
          Compared to lesional skin of patients with AD before UVA1 irradiation, the number of cells positive for cathepsin G within the dermal infiltrate decreased significantly after treatment. The decrease of cathepsin G+ cells was closely linked to a substantial clinical improvement in skin condition.
        
        
          Conclusions
          In summary, our findings demonstrated that medium-dose UVA1 irradiation leads to a modulation of the expression of cathepsin G in the dermal inflammatory infiltrate in patients with severe AD. Cathepsin G may attack laminin, proteoglycans, collagen I and insoluble fibronectin, to provoke proinflammatory events, to degrade the basement membrane, to destroy the tissue inhibitor of metalloproteinases and to increase the endothelial permeability. Therefore, its down-regulation by UVA1 phototherapy may induce the reduction of skin inflammation as well as improvement of the skin condition.
Patent AT-E399879-T1: [Translated] METHOD FOR DETERMINING VITAL SAMPLES

A method for determining ADP containing in a liquid sample by means of an enzymatic reaction, which comprises reacting the sample at 15 to 45  DEG C at least in the presence of glucose, ADP-dependent hexokinase, and oxidized NAD(P), a glucose-6-phosphate dehydrogenase, and one or more salts releasing ions selected among magnesium, cobalt, and manganese ions and then determining the ADP contained in the sample together with the AMP resulting from the reaction based on the amount of the reduced NAD(P) yielded. This method has advantages in that the limit of determination is high because ADP is determined based on the amount of the reduced NAD(P) yielded, and that since the reduced NAD (P) has a definite molecular extinction coefficient, the found value is highly reliable and uninfluenced by the reducing substances, etc., contained in the sample. <IMAGE>
Ibuprofen 400 mg is effective in women, and women are well represented in trials

Background
          A recent article in the New Scientist argued that women were under-represented in clinical trials which, until now, had masked the finding that ibuprofen 400 mg was ineffective in women.
        
        
          Methods
          Meta-analysis of randomised, double-blind placebo-controlled trials of ibuprofen 400 mg in acute pain, and use of individual patient information were planned to test the hypothesis that ibuprofen is ineffective in women. For each trial the proportion of women participating, the number of patients with at least 50% pain relief and the overall event rate for ibuprofen 400 mg and placebo was calculated. For each patient percentage pain relief was calculated, and the numbers of women and men achieving at least 50% pain relief used to calculate number-needed-to-treat (NNT) for ibuprofen 400 mg compared to placebo.
        
        
          Results
          Thirty-seven included trials had 3,577 patients, 67% of whom were women. The proportion with at least 50% pain relief was unaffected by how many women were included. In an analysis of 678 individual patients the proportion of women and men with at least 50% pain relief was the same, NNT 3.4 (2.6 to 4.6) and 2.5 (2.0 to 3.3) respectively.
        
        
          Conclusion
          There is no clinically meaningful difference in the efficacy of ibuprofen 400 mg between men and women experiencing moderate to severe postoperative pain and women were well represented.